Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
On March 26, 2025, Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), a profitable pharmaceutical company with a market capitalization of $2.85 billion and strong financial health according to InvestingPro analysis, disclosed that its Principal Accounting Officer, Kihara James, sold shares of the company’s common stock. According to the filing, James sold 1,095 shares at a price of $17.05 per share, totaling approximately $18,669. This transaction was part of a mandatory sale to cover withholding taxes and related items associated with the vesting of restricted stock units. The company maintains robust financial metrics, with a healthy current ratio of 2.38 and more cash than debt on its balance sheet.
In addition to the sale, James acquired 2,142 shares of common stock through the exercise of restricted stock units, though this transaction did not involve any direct financial exchange. Following these transactions, James holds 21,275 shares of Acadia Pharmaceuticals directly.
The transactions were part of a broader series of movements involving stock options and restricted stock units, which are common components of executive compensation packages.
In other recent news, Acadia Pharmaceuticals reported a 12% increase in revenue for the fourth quarter of 2024, reaching $259.6 million, contributing to a total annual revenue of $957.8 million, which is a 32% rise from the previous year. The strong performance was driven by DAYBUE sales, which surged 97% in 2024, and NUPLAZID sales, which grew by 11%. The company has projected 2025 revenue to be between $1.03 billion and $1.095 billion. Acadia is also expanding its sales force and preparing for international market entry. TD Cowen maintained a Buy rating on Acadia with a price target of $35, following the company’s earnings that exceeded expectations. Meanwhile, Citizens JMP adjusted its price target to $37 from $39 but retained a Market Outperform rating, citing the potential in Acadia’s commercial franchises and pipeline programs. Additionally, Acadia has issued new employee stock awards under its 2024 Inducement Plan to incentivize new hires. Lastly, a study published in the journal Med confirmed the safety and tolerability of DAYBUE for treating Rett syndrome in young children, supporting its FDA approval for patients aged two and older.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.